IM Cannabis Announces Ronen Zalayet as CEO, Replacing Oren Shuster
IM Cannabis announced on November 20 that Ronen Zalayet had become its chief executive, replacing Oren Shuster, who resigned. The appointment took effect on November 19. The company also named a new head of its Israeli medical-cannabis subsidiary and announced a change to its board. The company linked the changes to its stated aim of “evaluating and building technology-driven businesses beyond its core medical cannabis operations.” Zalayet has more than 25 years of financial leadership experience. He has served as chief financial officer of Nasdaq-listed Nexera Technologies, formerly Jeffs’ Brands, since October 2022, and was chief executive and a director of Shemen Oil and Gas Resources from July 2021 to December 2023. Shakked Shuster became chief executive of Focus Medical Herbs, the subsidiary through which IM Cannabis operates its Israeli medical-cannabis business, also effective November 19. He replaces Oren Shuster in that role. He joined the company in July 2020, helped establish its Canada-to-Israel import program beginning in mid-2021, and has worked full time in its Israeli operations since May 2026. Oren Shuster also resigned from the parent company’s board effective November 19, but will remain a director of its Israeli subsidiaries. Ohad Melnik was appointed to fill the board seat vacated by Einat Zakariya in September. The board determined that Melnik meets Nasdaq’s independence requirements. His appointment remains subject to approval by the Israel Medical Cannabis Agency. Melnik served on Formula Systems’ board from January 2019 to May 2024. He currently advises iFOREX Group on international online payments and is a director of its Israeli subsidiary, iFOR Fintech. IM Cannabis, which trades on Nasdaq under IMCC, imports and distributes medical cannabis through Israeli subsidiaries and operates medical-cannabis pharmacies and online platforms.

Commentary